Model‐based simulation to support the approval of isatuximab alone or with dexamethasone for the treatment of relapsed/refractory multiple myeloma in Japanese patients

• Hauptverfasser: Hoai‐Thu Thai (Verfasst von), Kimiko Koiwai (Verfasst von), Yoshihisa Shitara (Verfasst von), Hirotaka Kazama (Verfasst von), Jean‐Baptiste Fau (Verfasst von), Dorothée Semiond (Verfasst von), Christine Veyrat‐Follet (Verfasst von)
• Format: Buch
• Veröffentlicht: Wiley, 2023-12-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Abstract This study aimed to support dosing regimen selection for isatuximab as a single agent or in combination with dexamethasone for Japanese patients with relapsed/refractory multiple myeloma (RRMM). A joint model characterizing the dynamics of serum M‐protein kinetics and its association with p...